Skip to content
lifestyle.lincolnlabs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ABLi Therapeutics
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
August 4, 2026
ABLi Therapeutics Appoints Industry Veteran Dr. Rachelle S. Doody to its Board of Directors
May 6, 2026
ABLi Therapeutics to Present at the Citizens Life Sciences Conference
March 5, 2026
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease
February 20, 2026